- Home
- LOGC vs PRQR Comparison
LOGC vs PRQR Comparison
Compare LOGC & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOGC
- PRQR
- Stock Information
- Founded
- LOGC 2010
- PRQR 2012
- Country
- LOGC United States
- PRQR Netherlands
- Employees
- LOGC N/A
- PRQR N/A
- Industry
- LOGC Catalog/Specialty Distribution
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- LOGC Consumer Discretionary
- PRQR Health Care
- Exchange
- LOGC Nasdaq
- PRQR Nasdaq
- Market Cap
- LOGC 149.0M
- PRQR 153.5M
- IPO Year
- LOGC 2020
- PRQR 2014
- Fundamental
- Price
- LOGC $6.30
- PRQR $3.78
- Analyst Decision
- LOGC
- PRQR Strong Buy
- Analyst Count
- LOGC 0
- PRQR 4
- Target Price
- LOGC N/A
- PRQR $3.38
- AVG Volume (30 Days)
- LOGC 282.2K
- PRQR 3.3M
- Earning Date
- LOGC 11-05-2024
- PRQR 11-05-2024
- Dividend Yield
- LOGC N/A
- PRQR N/A
- EPS Growth
- LOGC N/A
- PRQR N/A
- EPS
- LOGC N/A
- PRQR N/A
- Revenue
- LOGC $156,000,000.00
- PRQR $16,902,389.00
- Revenue This Year
- LOGC N/A
- PRQR $305.55
- Revenue Next Year
- LOGC $422.91
- PRQR N/A
- P/E Ratio
- LOGC N/A
- PRQR N/A
- Revenue Growth
- LOGC N/A
- PRQR 290.57
- 52 Week Low
- LOGC $3.55
- PRQR $1.11
- 52 Week High
- LOGC $6.95
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- LOGC 75.25
- PRQR 71.58
- Support Level
- LOGC $5.79
- PRQR $1.83
- Resistance Level
- LOGC $6.34
- PRQR $4.62
- Average True Range (ATR)
- LOGC 0.18
- PRQR 0.42
- MACD
- LOGC 0.05
- PRQR 0.25
- Stochastic Oscillator
- LOGC 94.59
- PRQR 70.53
About LOGC ContextLogic Inc.
ContextLogic Inc is an online shopping store. The store provides personalized products, clothing products, accessories, gaming products and equipment, cosmetics, plastic products, mobile covers, and other products. Geographically, it derives a majority of its revenue from Europe and also has a presence in North America; South America, and other countries.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.